- Zacks Small Cap Research•last month
By Grant Zeng, CFA OTC:GOVX Update on Second Quarter Financials Total revenue was $166,280 for the three-month ended June 30, 2016, related to grants from the NIH in support of its HIV/AIDS vaccine development ...
- Marketwired•2 months ago
GeoVax Labs, Inc. , a biotechnology company developing human vaccines using its novel platform technology, announced its financial results for the three and six months ended June 30, 2016 and provided ...
- Marketwired•2 months agoGeoVax Awarded NIH Contract for up to $7.8 Million to Manufacture HIV Vaccine for Advanced Human Clinical Trials
GeoVax Labs, Inc. , a biotechnology company developing human vaccines, announced today that the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health has awarded ...
GeoVax Labs, Inc. (GOVX)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||0.07 - 0.08|
|52wk Range||0.05 - 0.14|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-0.82|
|Avg Vol (3m)||373,675|
|Dividend & Yield||N/A (N/A)|